2975-36-2
中文名稱
哌卡嗪鹽酸鹽
英文名稱
10-[(1-methyl-3-piperidyl)methyl]-10H-phenothiazine monohydrochloride
CAS
2975-36-2
分子式
C19H23ClN2S
分子量
346.917
MOL 文件
2975-36-2.mol
更新日期
2025/03/12 16:18:29
2975-36-2 結構式
基本信息
中文別名
哌卡嗪鹽酸鹽甲哌啶嗪鹽酸鹽
英文別名
Mepazine hydrochloride10-((1-methylpiperidin-3-yl)methyl)-10H-phenothiazine hydrochloride
10-[(1-methyl-3-piperidyl)methyl]-10H-phenothiazine monohydrochloride
10H-Phenothiazine, 10-[(1-methyl-3-piperidinyl)methyl]-,monohydrochloride
所屬類別
有機原料：羧酸類化合物及衍生物物理化學性質
熔點180-181 °C
沸點180-183 °C(Press: 0.5 Torr)
儲存條件-20°C儲存
溶解度DMSO: 50 mg/mL (144.13 mM)
形態(tài)Solid
顏色White to off-white
水溶解性H2O: 2.5mg/mL
DMSO: 25mg/mL
DMSO: 25mg/mL
哌卡嗪鹽酸鹽價格(試劑級)
| 報價日期 | 產品編號 | 產品名稱 | CAS號 | 包裝 | 價格 |
| 2025/02/08 | HY-121282A | 哌卡嗪鹽酸鹽 Mepazine hydrochloride | 2975-36-2 | 25 mg | 1150元 |
| 2025/02/08 | HY-121282A | 哌卡嗪鹽酸鹽 Mepazine hydrochloride | 2975-36-2 | 10mM * 1mLin DMSO | 1270元 |
| 2025/02/08 | HY-121282A | 哌卡嗪鹽酸鹽 Mepazine hydrochloride | 2975-36-2 | 50mg | 1750元 |
常見問題列表
生物活性
Mepazine hydrochloride (Pecazine hydrochloride) 是一種有效的選擇性 MALT1 蛋白酶抑制劑。Mepazine hydrochloride 抑制全長 GSTMALT1 和 GSTMALT1 325-760 段的IC50 分別為 0.83 和 0.42 μM。Mepazine hydrochloride 通過增強細胞凋亡 (apoptosis) 來影響 ABC-DLBCL 細胞的生存能力。靶點
MALT1
體外研究
Mepazine (5-20 μM; 4 days) causes a decrease of cell viability in the activated B cell subtype of diffuse large B cell lymphoma (ABCDLBCL) cells, without significantly affecting GCB-DLBCL cells.
Cell Viability Assay
| Cell Line: | ABC-DLBCL cell lines (HBL1, OCI-Ly3, U2932, TMD8, OCI-Ly10) and GCB-DLBCL cell lines (BJAB, Su-DHL-6, Su-DHL-4) |
| Concentration: | 5, 10, and 20 μM |
| Incubation Time: | 4 days |
| Result: | Caused a decrease of cell viability in the ABC-DLBCL cells HBL1, OCI-Ly3, U2932, and TMD8, without significantly affecting GCB-DLBCL cells. |
體內研究
Mepazine (16 mg/kg; intraperitoneal administration) interferes with growth and induces apoptosis of ABC-DLBCL cell line OCI-Ly10 in NOD/scid IL-2Rg null (NSG) mice with a murine DLBCL xenogeneic tumor model. Daily administration of Mepazine strongly impairs the expansion of the ABC-DLBCL cell line OCI-Ly10.
| Animal Model: | 6- to 8-week-old female NOD.Cg- Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice with a murine DLBCL xenogeneic tumor model |
| Dosage: | 400 μg per animal (25 g), corresponding to approximately 16 mg/kg |
| Administration: | Intraperitoneal administration; started 1 or 12 days after transplantation and given continuously every 24 hr; daily application |
| Result: | Daily administration strongly impaired the expansion of the ABC-DLBCL cell line OCI-Ly10. |